Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $701 | $675 | $667 | $542 |
| % Growth | 3.9% | 1.2% | 23.1% | – |
| Cost of Goods Sold | $170 | $185 | $199 | $140 |
| Gross Profit | $531 | $490 | $468 | $401 |
| % Margin | 75.7% | 72.6% | 70.1% | 74.1% |
| R&D Expenses | $82 | $76 | $85 | $56 |
| G&A Expenses | $122 | $116 | $110 | $88 |
| SG&A Expenses | $294 | $269 | $255 | $199 |
| Sales & Mktg Exp. | $172 | $153 | $145 | $111 |
| Other Operating Expenses | $228 | $57 | $68 | $56 |
| Operating Expenses | $604 | $403 | $408 | $311 |
| Operating Income | -$73 | $88 | $60 | $90 |
| % Margin | -10.5% | 13% | 9% | 16.6% |
| Other Income/Exp. Net | $10 | -$26 | -$47 | -$34 |
| Pre-Tax Income | -$63 | $62 | $13 | $56 |
| Tax Expense | $36 | $20 | -$3 | $14 |
| Net Income | -$100 | $42 | $16 | $42 |
| % Margin | -14.2% | 6.2% | 2.4% | 7.8% |
| EPS | -2.15 | 0.91 | 0.35 | 0.95 |
| % Growth | -336.3% | 160% | -63.2% | – |
| EPS Diluted | -2.15 | 0.89 | 0.34 | 0.92 |
| Weighted Avg Shares Out | 46 | 46 | 46 | 44 |
| Weighted Avg Shares Out Dil | 46 | 52 | 47 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $11 | $5 | $1 |
| Interest Expense | $17 | $17 | $36 | $29 |
| Depreciation & Amortization | $79 | $76 | $92 | $29 |
| EBITDA | $29 | $155 | $140 | $114 |
| % Margin | 4.2% | 22.9% | 21.1% | 21% |